Cover Image
Market Research Report
Product code 
1003365

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2021 - 2028

Published: | Grand View Research, Inc. | 118 Pages | Delivery time: 2-10 business days

Price

Back to Top
Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2021 - 2028
Published: April 15, 2021
Grand View Research, Inc.
Content info: 118 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

Breast Cancer Diagnostics Market Growth & Trends

The global breast cancer diagnostics market size is expected to reach USD 6.8 billion by 2028, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 7.0% from 2021 to 2028. The growth is largely attributable to the increasing geriatric population exposed to the risk of breast cancer and early detection coupled with increasing awareness about breast cancer.

The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth. This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient recalls. Rapid technological advancements are a major factor expected to drive the market over the coming years.

Companies are adopting strategies that allow them to use their resources to aid in the development of new products, as well as enhance their supply chain. In November 2019, Exact Sciences Corporation announced the acquisition of Genomic Health, which was expected to help enhance the company's market position and offerings by acquiring its product portfolio. In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately US$ 230 million. Biotheranostics is a commercial-stage molecular diagnostics provider for breast and metastatic cancers.

The increasing launch of predictive and companion diagnostic tests for breast cancer is expected to boost the market growth. Recent launches in the segment include BRACAnalysis CDx by Myriad Genetics, which received FDA approval in 2018 as breast cancer companion diagnostics. In May 2019, QIAGEN introduced therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for Novartis proprietary PIQRAY in guiding treatment decisions from tissue and liquid biopsy.

In January 2019, the Fujifilm Holdings Corporation introduced its Tomosynthesis Biopsy option for ASPIRE Cristalle mammography system. This technique was expected to enable physicians to detect breast cancers more efficiently compared to others by providing an enhanced 3D image and a digital mammogram.

However, there are specific risk factors associated with these imaging procedures. They involve administering high doses of fluorescent and barium contrast agents, as well as radiation exposure in the case of imaging and endoscopic procedures, which can cause several adverse effects such as nausea or diarrhea. The risks of ionizing radiation exposure associated with the use of CT, MRI, and X-rays, as well as the use of radioactive tracer injections in PET can limit the adoption of such screening procedures. Therefore, factors such as adverse effects of imaging act as a challenge for the companies in this market.

Breast Cancer Diagnostics Market Report Highlights

The imaging segment held the largest revenue share in 2020 and the blood tests segment is expected to grow at the fastest rate

By product, the instrument-based products segment accounted for the largest revenue share in 2020 due to government initiatives such as mandatory screening in developed countries such as the U.S., Canada, and the U.K. for women above 45 years of age, increasing the overall testing and screening of breast cancer

The platform-based products segment is expected to witness the fastest growth over the forecast period. These tests are mostly used for assessing the efficacy of chemotherapy and targeted therapy in women

By application, the diagnostic and predictive segment dominated the market in 2020 and the prognostic segment is expected to witness the fastest CAGR over the forecast period due to increasing collaborations and efforts for advancements in diagnostics

The hospitals and clinics segment dominated the market in 2020

The medical labs and diagnostics centers segment is expected to witness the fastest CAGR over the forecast period due to an increase in platform-based testing such as NGS, and PCR

Product Code: GVR-3-68038-694-3

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Dashboard Analysis
  • 2.2 Segment Outlook

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Parent Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Regulatory and Reimbursement Framework
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Increasing Incidence Of Breast Cancer
      • 3.4.1.2 Technological Advancements
      • 3.4.1.3 Favorable Reimbursement Framework For Breast Cancer Diagnosis
      • 3.4.1.4 Early Detection And Increase In Awareness About Breast Cancer
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 Adverse Effects Of Screening Procedures
  • 3.5 Breast Cancer Diagnostics Market Analysis Tools
    • 3.5.1 Pestel Analysis
    • 3.5.2 Industry Analysis - Porter's

Chapter 4 Breast Cancer Diagnostics Market: Type Segment Analysis

  • 4.1 Breast Cancer Diagnostics Market: Type Movement Analysis
  • 4.2 Imaging
    • 4.2.1 Imaging market, 2017 - 2028 (USD Million)
  • 4.3 Biopsy
    • 4.3.1 Biopsy market, 2017 - 2028 (USD Million)
  • 4.4 Genomic Tests
    • 4.4.1 Genomic tests market, 2017 - 2028 (USD Million)
  • 4.5 Blood Tests
    • 4.5.1 Blood tests market, 2017 - 2028 (USD Million)
  • 4.6 Others
    • 4.6.1 Others market, 2017 - 2028 (USD Million)

Chapter 5 Breast Cancer Diagnostics Market: Product Segment Analysis

  • 5.1 Breast Cancer Diagnostics Market: Product Movement Analysis
  • 5.2 Platform-based Products
    • 5.2.1 Platform based products market, 2017 - 2028 (USD Million)
    • 5.2.2 Next-generation sequencing
      • 5.2.2.1 Next-Generation Sequencing market, 2017 - 2028 (USD Million)
    • 5.2.3 Microarrays
      • 5.2.3.1 Microarrays market, 2017 - 2028 (USD Million)
    • 5.2.4 PCR
      • 5.2.4.1 PCR market, 2017 - 2028 (USD Million)
    • 5.2.5 Others
      • 5.2.5.1 Others market, 2017 - 2028 (USD Million)
  • 5.3 Instrument-based Products
    • 5.3.1 Instrument-based products market, 2017 - 2028 (USD Million)
    • 5.3.2 Imaging
      • 5.3.2.1 Imaging market, 2017 - 2028 (USD Million)
    • 5.3.3 Biopsy
      • 5.3.3.1 Biopsy market, 2017 - 2028 (USD Million)

Chapter 6 Breast Cancer Diagnostics Market: Application Segment Analysis

  • 6.1 Breast Cancer Diagnostics Market: Application Movement Analysis
  • 6.2 Screening
    • 6.2.1 Screening market, 2017 - 2028 (USD Million)
  • 6.3 Diagnostic & Predictive
    • 6.3.1 Diagnostic and predictive market, 2017 - 2028 (USD Million)
  • 6.4 Prognostic
    • 6.4.1 Prognostic market, 2017 - 2028 (USD Million)
  • 6.5 Research
    • 6.5.1 Research market, 2017 - 2028 (USD Million)

Chapter 7 Breast Cancer Diagnostics Market: End-use Segment Analysis

  • 7.1 Breast Cancer Diagnostics Market: End-use Movement Analysis
  • 7.2 Hospitals & Clinics
    • 7.2.1 Hospitals & clinics market, 2017-2028 (USD Million)
  • 7.3 Diagnostic Centers and Medical Laboratories
    • 7.3.1 Diagnostic centers and medical laboratories market, 2017-2028 (USD Million)
  • 7.4 Others
    • 7.4.1 Others market, 2017-2028 (USD Million)

Chapter 8 Breast Cancer Diagnostics Market: Segment Analysis, By Region, 2017-2028 (USD Million)

  • 8.1 Breast Cancer Diagnostics Market: Regional Movement Analysis
  • 8.2 Market Size, & Forecasts, Revenue and Trend Analysis, 2020 to 2028
    • 8.2.1 North America
      • 8.2.1.1 North America market estimates and forecast, 2017-2028 (USD Million)
      • 8.2.1.2 U.S.
      • 8.2.1.2.1 U.S. breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.1.3 Canada
      • 8.2.1.3.1 Canada breast cancer diagnostics market, 2017 - 2028 (USD Million)
    • 8.2.2 Europe
      • 8.2.2.1 Europe breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.2.2 U.K.
      • 8.2.2.2.1 U.K. breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.2.3 Germany
      • 8.2.2.3.1 Germany breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.2.4 Spain
      • 8.2.2.4.1 Spain breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.2.5 France
      • 8.2.2.5.1 France breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.2.6 Italy
      • 8.2.2.6.1 Italy breast cancer diagnostics market, 2017 - 2028 (USD Million)
    • 8.2.3 Asia Pacific
      • 8.2.3.1 Asia Pacific breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.3.2 Japan
      • 8.2.3.2.1 Japan breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.3.3 China
      • 8.2.3.3.1 China breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.3.4 India
      • 8.2.3.4.1 India breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.3.5 South Korea
      • 8.2.3.5.1 South Korea breast cancer diagnostics market, 2017 - 2028 (USD Million)
    • 8.2.4 Latin America
      • 8.2.4.1 Latin America breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.4.2 Brazil
      • 8.2.4.2.1 Brazil breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.4.3 Mexico
      • 8.2.4.3.1 Mexico breast cancer diagnostics market, 2017 - 2028 (USD Million)
    • 8.2.5 MEA
      • 8.2.5.1 MEA breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.5.2 South Africa
      • 8.2.5.2.1 South Africa breast cancer diagnostics market, 2017 - 2028 (USD Million)
      • 8.2.5.3 Saudi Arabia
      • 8.2.5.3.1 Saudi Arabia breast cancer diagnostics market, 2017 - 2028 (USD Million)

Chapter 9 Breast Cancer Diagnostics Market: Competitive Analysis

  • 9.1 Recent developments and impact analysis, by key market participants
    • 9.1.1 Ansoff Matrix
  • 9.2 Company Categorization
    • 9.2.1 Innovators
    • 9.2.2 Market Leaders
  • 9.3 Vendor Landscape
    • 9.3.1 List Of Key Distributors And Channel Partners
    • 9.3.2 Key Customers
    • 9.3.3 Key Company Market Share Analysis, 2020
  • 9.4 Public Companies
    • 9.4.1 Company Market Position Analysis
    • 9.4.2 Competitive Dashboard Analysis
      • 9.4.2.1 Market Differentiators
  • 9.5 Private Companies
    • 9.5.1 List Of Key Emerging Companies
  • 9.6 Major Deals and Strategic Alliances Analysis
    • 9.6.1 New Product Launches
    • 9.6.2 Joint Ventures
    • 9.6.3 Acquisitions
    • 9.6.4 Licensing And Partnerships
    • 9.6.5 Conferences And Campaigns
  • 9.7 Company Profiles
    • 9.7.1 KONINKLIJKE PHILIPS N.V.
      • 9.7.1.1 Company overview
      • 9.7.1.2 Financial performance
      • 9.7.1.3 Product benchmarking
      • 9.7.1.4 Strategic initiatives
    • 9.7.2 DANAHER CORPORATION
      • 9.7.2.1 Company overview
      • 9.7.2.2 Financial performance
      • 9.7.2.3 Product benchmarking
      • 9.7.2.4 Strategic initiatives
    • 9.7.3 HOLOGIC INC
      • 9.7.3.1 Company overview
      • 9.7.3.2 Financial performance
      • 9.7.3.3 Product benchmarking
      • 9.7.3.4 Strategic initiatives
    • 9.7.4 BECTON, DICKINSON AND COMPANY
      • 9.7.4.1 Company overview
      • 9.7.4.2 Financial performance
      • 9.7.4.3 Product benchmarking
      • 9.7.4.4 Strategic initiatives
    • 9.7.5 QIAGEN
      • 9.7.5.1 Company overview
      • 9.7.5.2 Financial performance
      • 9.7.5.3 Product benchmarking
      • 9.7.5.4 Strategic initiatives
    • 9.7.6 THERMO FISHER SCIENTIFIC, INC.
      • 9.7.6.1 Company overview
      • 9.7.6.2 Financial performance
      • 9.7.6.3 Product benchmarking
      • 9.7.6.4 Strategic initiatives
    • 9.7.7 GENOMIC HEALTH (EXACT SCIENCES)
      • 9.7.7.1 Company overview
      • 9.7.7.2 Financial performance
      • 9.7.7.3 Product benchmarking
      • 9.7.7.4 Strategic initiatives
    • 9.7.8 MYRIAD GENETICS, INC.
      • 9.7.8.1 Company overview
      • 9.7.8.2 Financial performance
      • 9.7.8.3 Product benchmarking
      • 9.7.8.4 Strategic initiatives
    • 9.7.9 ARGON MEDICAL DEVICES INC.
      • 9.7.9.1 Company overview
      • 9.7.9.2 Product benchmarking
      • 9.7.9.3 Strategic initiatives
    • 9.7.10 F. HOFFMANN-LA ROCHE LTD
      • 9.7.10.1 Company overview
      • 9.7.10.2 Financial performance
      • 9.7.10.3 Product benchmarking
      • 9.7.10.4 Strategic initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 3 North America breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 4 North America breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 5 North America breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 6 U.S. breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 7 U.S. breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 8 U.S. breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 9 U.S. breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 10 Canada breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 11 Canada breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 12 Canada breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 13 Canada breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 14 Europe breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 15 Europe breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 16 Europe breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 17 Europe breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 18 U.K. breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 19 U.K. breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 20 U.K. breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 21 U.K. breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 22 Germany breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 23 Germany breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 24 Germany breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 25 Germany breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 26 France breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 27 France breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 28 France breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 29 France breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 30 Spain breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 31 Spain breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 32 Spain breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 33 Spain breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 34 Italy breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 35 Italy breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 36 Italy breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 37 Italy breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 38 Asia Pacific breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 39 Asia Pacific breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 40 Asia Pacific breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 41 Asia Pacific breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 42 Japan breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 43 Japan breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 44 Japan breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 45 Japan breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 46 China breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 47 China breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 48 China breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 49 China breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 50 India breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 51 India breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 52 India breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 53 India breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 54 South Korea breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 55 South Korea breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 56 South Korea breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 57 South Korea breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 58 Latin America breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 59 Latin America breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 60 Latin America breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 61 Latin America breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 62 Brazil breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 63 Brazil breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 64 Brazil breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 65 Brazil breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 66 Mexico breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 67 Mexico breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 68 Mexico breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 69 Mexico breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 70 Middle East & Africa breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 71 Middle East & Africa breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 72 Middle East & Africa breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 73 Middle East & Africa breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 74 South Africa breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 75 South Africa breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 76 South Africa breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 77 South Africa breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 78 Saudi Arabia breast cancer diagnostics market estimates and forecasts, by type, 2017 - 2028 (USD Million)
  • TABLE 79 Saudi Arabia breast cancer diagnostics market estimates and forecasts, by product, 2017 - 2028 (USD Million)
  • TABLE 80 Saudi Arabia breast cancer diagnostics market estimates and forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 81 Saudi Arabia breast cancer diagnostics market estimates and forecasts, by end use, 2017 - 2028 (USD Million)

List of Figures

  • Fig. 1 Breast cancer diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Breast cancer diagnostics market, Dashboard, 2020
  • Fig. 10 Breast cancer diagnostics segment outlook (2020)
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Breast Cancer Diagnostics Market Driver Impact
  • Fig. 13 Breast Cancer Diagnostics Market Restraint Impact
  • Fig. 14 SWOT Analysis, By Factor (Political & Legal Economic and Technological)
  • Fig. 15 Porter's Five Forces analysis
  • Fig. 16 Breast cancer diagnostics market type outlook: Key takeaways
  • Fig. 17 Breast cancer diagnostics market: Type movement analysis
  • Fig. 18 Imaging market, 2017 - 2028 (USD Million)
  • Fig. 19 Biopsy market, 2017 - 2028 (USD Million)
  • Fig. 20 Genomic tests market, 2017 - 2028 (USD Million)
  • Fig. 21 Blood tests market, 2017 - 2028 (USD Million)
  • Fig. 22 Others market, 2017 - 2028 (USD Million)
  • Fig. 23 Breast cancer diagnostics market product outlook: Key takeaways
  • Fig. 24 Breast cancer diagnostics market: Product movement analysis
  • Fig. 25 Platform based products market, 2017 - 2028 (USD Million)
  • Fig. 26 Next-generation sequencing market, 2017 - 2028 (USD Million)
  • Fig. 27 Microarrays market, 2017 - 2028 (USD Million)
  • Fig. 28 PCR market, 2017 - 2028 (USD Million)
  • Fig. 29 Others market, 2017 - 2028 (USD Million)
  • Fig. 30 Instrument-based products market, 2017 - 2028 (USD Million)
  • Fig. 31 Imaging market, 2017 - 2028 (USD Million)
  • Fig. 32 Biopsy market, 2017 - 2028 (USD Million)
  • Fig. 33 Breast cancer diagnostics market application outlook: Key takeaways
  • Fig. 34 Breast cancer diagnostics market: Application movement analysis
  • Fig. 35 Screening market, 2017 - 2028 (USD Million)
  • Fig. 36 Diagnostic and predictive market, 2017 - 2028 (USD Million)
  • Fig. 37 Prognostic market, 2017 - 2028 (USD Million)
  • Fig. 38 Research market, 2017 - 2028 (USD Million)
  • Fig. 39 Breast cancer diagnostics market end-use outlook: Key takeaways
  • Fig. 40 Breast cancer diagnostics market: End-use movement analysis
  • Fig. 41 Hospitals & clinics market, 2017-2028 (USD million)
  • Fig. 42 Diagnostic centers and medical laboratories market, 2017-2028 (USD million)
  • Fig. 43 Others market, 2017-2028 (USD million)
  • Fig. 44 Regional marketplace: Key takeaways
  • Fig. 45 Breast cancer diagnostics market: Regional movement analysis
  • Fig. 46 North America
  • Fig. 47 North America breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 48 U.S.
  • Fig. 49 U.S. breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 50 Canada
  • Fig. 51 Canada breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 52 Europe
  • Fig. 53 Europe breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 54 U.K.
  • Fig. 55 U.K. breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 56 Germany
  • Fig. 57 Germany breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 58 Spain
  • Fig. 59 Spain breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 60 France
  • Fig. 61 France breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 62 Italy
  • Fig. 63 Italy breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 64 Asia Pacific
  • Fig. 65 Asia Pacific breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 66 Japan
  • Fig. 67 Japan breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 68 China
  • Fig. 69 China breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 70 India
  • Fig. 71 India breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 72 South Korea
  • Fig. 73 South Korea breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 74 Latin America
  • Fig. 75 Latin America breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 76 Brazil
  • Fig. 77 Brazil breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 78 Mexico
  • Fig. 79 Mexico breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 80 Middle East and Africa
  • Fig. 81 MEA breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 82 South Africa
  • Fig. 83 South Africa breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 84 Saudi Arabia
  • Fig. 85 Saudi Arabia breast cancer diagnostics market, 2017 - 2028 (USD Million)
  • Fig. 86 Ansoff Matrix
  • Fig. 87 Company market share analysis, 2020
  • Fig. 88 Company market position analysis
  • Fig. 89 Company market position analysis
  • Fig. 90 Market differentiators
  • Fig. 91 Strategy mapping